Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Krn 7000
2. Krn 7000, 1s-(1r*,2r*,3s*)-beta-d-galacto Isomer
3. Krn-7000
4. Krn7000
1. Krn7000
2. 158021-47-7
3. Krn 7000
4. Krn-7000
5. Alpha-galactosylceramide
6. .alpha.-galcer
7. Ccris 8968
8. Agl-582
9. Galalpha-cer(t18:0/26:0)
10. Chebi:466659
11. 1-o-(alpha-d-galactopyranosyl)-n-hexacosanoylphytosphingosine
12. Alpha-galcer(t18:0/26:0)
13. Wx671898jf
14. Rgi-7000
15. (2s,3s,4r)-1-o-(alpha-d-galactosyl)-n-hexacosanoyl-2-amino-1,3,4-octadecanetriol
16. N-{(1s,2r,3s)-1-[(alpha-d-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl}hexacosanamide
17. N-[(2s,3s,4r)-1-(alpha-d-galactopyranosyloxy)-3,4-dihydroxyoctadecan-2-yl]hexacosanamide
18. N-((2s,3s,4r)-3,4-dihydroxy-1-(((2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)octadecan-2-yl)hexacosanamide
19. Unii-wx671898jf
20. Rgi-2001
21. Alpha-gc(c26)
22. Alpha-gc (c26)
23. Alpha-galactosyl Ceramide
24. Epitope Id:130694
25. Schembl512949
26. Chembl384200
27. Dtxsid40935847
28. Chemid158021477
29. Glxc-26234
30. Ex-a5755
31. Mfcd00939559
32. Zinc87496076
33. Db12232
34. Ac-31508
35. N-[(2s,3s,4r)-3,4-dihydroxy-1-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]hexacosanamide
36. C16892
37. Alpha-galactosylceramide(a-gal-cer) (synthetic)
38. Q27105159
39. 1-o-(alpha-d-galactosyl)-n-hexacosanoylphytosphingosine
40. (2s,3s,4r)-1-o-(alpha-d-galactosyl)-n-hexacosanoyl-2-amino-1,3,4-octadecanetriol, >=95% (tlc)
41. Hexacosanamide, N-((1s,2s,3r)-1-((.alpha.-d-galactopyranosyloxy)methyl)-2,3-dihydroxyheptadecyl)-
42. Hexacosanamide, N-(1-((alpha-d-galactopyranosyloxy)methyl)-2,3-dihdyroxyheptadecyl)-, (1s-(1r*,2r*,3s*))-
43. Hexacosanamide, N-[(1s,2s,3r)-1-[(alpha-d-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl]-
44. Hexacosanamide, N-[(1s,2s,3r)-1-[(alpha-d-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl]- (9ci)
45. Hexacosanamide, N-[1-[(alpha-d-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl]-, [1s-(1r*,2r*,3s*)]-
46. N-((2s,3s,4r)-3,4-dihydroxy-1-(3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)octadecan-2-yl)hexaicosanamide
47. N-{(1s,2s,3r)-1-[(alpha-d-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl}hexacosanamide
48. Wurcs=2.0/1,1,0/[a2112h-1a_1-5_1*occ^sc^sc^rcccccccccccccc/6o/5o/4ncccccccccccccccccccccccccc/24=o]/1/
| Molecular Weight | 858.3 g/mol |
|---|---|
| Molecular Formula | C50H99NO9 |
| XLogP3 | 16 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 44 |
| Exact Mass | 857.73198374 g/mol |
| Monoisotopic Mass | 857.73198374 g/mol |
| Topological Polar Surface Area | 169 Ų |
| Heavy Atom Count | 60 |
| Formal Charge | 0 |
| Complexity | 928 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
ABOUT THIS PAGE
25
PharmaCompass offers a list of RGI-2001 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right RGI-2001 manufacturer or RGI-2001 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred RGI-2001 manufacturer or RGI-2001 supplier.
PharmaCompass also assists you with knowing the RGI-2001 API Price utilized in the formulation of products. RGI-2001 API Price is not always fixed or binding as the RGI-2001 Price is obtained through a variety of data sources. The RGI-2001 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A KRN7000 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of KRN7000, including repackagers and relabelers. The FDA regulates KRN7000 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. KRN7000 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A KRN7000 supplier is an individual or a company that provides KRN7000 active pharmaceutical ingredient (API) or KRN7000 finished formulations upon request. The KRN7000 suppliers may include KRN7000 API manufacturers, exporters, distributors and traders.
click here to find a list of KRN7000 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A KRN7000 DMF (Drug Master File) is a document detailing the whole manufacturing process of KRN7000 active pharmaceutical ingredient (API) in detail. Different forms of KRN7000 DMFs exist exist since differing nations have different regulations, such as KRN7000 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A KRN7000 DMF submitted to regulatory agencies in the US is known as a USDMF. KRN7000 USDMF includes data on KRN7000's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The KRN7000 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of KRN7000 suppliers with USDMF on PharmaCompass.
KRN7000 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of KRN7000 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right KRN7000 GMP manufacturer or KRN7000 GMP API supplier for your needs.
A KRN7000 CoA (Certificate of Analysis) is a formal document that attests to KRN7000's compliance with KRN7000 specifications and serves as a tool for batch-level quality control.
KRN7000 CoA mostly includes findings from lab analyses of a specific batch. For each KRN7000 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
KRN7000 may be tested according to a variety of international standards, such as European Pharmacopoeia (KRN7000 EP), KRN7000 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (KRN7000 USP).
